<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225471</url>
  </required_header>
  <id_info>
    <org_study_id>IMU-H21-40-PⅠ/Ⅱ</org_study_id>
    <nct_id>NCT01225471</nct_id>
  </id_info>
  <brief_title>Novel Peptide Vaccination for Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iwate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iwate Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical efficacy of novel peptide&#xD;
      vaccination for advanced prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cell division cycle associated gene 1(CDCA1) has been identified using genome-wide expression&#xD;
      profile analysis by the use of cDNA microarray in our previous studies. We have determined&#xD;
      the HLA-A*2402 restricted epitope peptides derived from CDCA1, CDCA1-A24-56. This epitope&#xD;
      showed strong IFN-g production when stimulated with the appropriate targets expressed the&#xD;
      appropriate protein and HLA-A*2402. Furthermore, when vaccinated this peptide, specific CTL&#xD;
      was determined after the vaccination. Therefore we focused on the safety and efficacy of&#xD;
      novel vaccination for the advanced prostate cancer patients who already showed resistance to&#xD;
      standard hormonal therapy and chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility (toxicities as assessed by NCI-CTCAE version 3)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate as assessed by RECIST criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of PSA</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTL response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 8 population</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in level of regulatory T cells</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS and OS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDCA1</intervention_name>
    <description>CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DISEASE CHARACTERISTICS advanced prostate cancer which already showed resistance to&#xD;
        standard treatments&#xD;
&#xD;
        PATIENTS CHARACTERISTICS&#xD;
&#xD;
          1. Patients who showed resistance to hormonal therapy and chemotherapy&#xD;
&#xD;
          2. Histological diagnosis is adenocarcinoma&#xD;
&#xD;
          3. HLA-A*2402&#xD;
&#xD;
          4. ECOG performance status of 0 to 2&#xD;
&#xD;
          5. Age ≥ 20 years, ≤85 years&#xD;
&#xD;
          6. WBC≥ 2,000/mm³, ≤12000/mm³ hemoglobin≥ 8.0g/dl Platelet count ≥ 70000/mm³ AST, ALT&#xD;
             ≤100 IU/l Total bilirubin ≤ 1.5 mg/dl Creatinine ≤ 1.0 mg/dl PaO2≥ 70mmHg&#xD;
&#xD;
          7. life expectancy ≥ 2months&#xD;
&#xD;
          8. Able and willing to give valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (women of childbearing potential: Refusal or inability to use effective&#xD;
             means of contraception)&#xD;
&#xD;
          2. Breastfeeding&#xD;
&#xD;
          3. Patients willing to childbearing ( Refusal or inability to use effective means of&#xD;
             contraception)&#xD;
&#xD;
          4. Serious infections requiring antibiotics&#xD;
&#xD;
          5. Concomitant treatment with steroids or immunosuppressing agent&#xD;
&#xD;
          6. Other malignancy difficult to control.&#xD;
&#xD;
          7. Decision of unsuitableness by principal investigator or physician-in-charge&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoaki Fujioka, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Urology, Iwate Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iwate Medical University School of Medicine</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Departmet of Urology</name_title>
    <organization>Iwate Medical University</organization>
  </responsible_party>
  <keyword>novel epitope peptide</keyword>
  <keyword>CTL</keyword>
  <keyword>advanced prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

